Background: Cisplatin is one of the most widely used chemotherapeutic agents, but the risk of nephrotoxicity frequently hinders the use of higher doses to maximize its antineoplastic effects. The lack of early biomarkers has impaired our ability to initiate potential therapeutic or preventive interventions in cisplatin nephrotoxicity in a timely manner. In this study, we have explored the expression and urinary excretion of neutrophil gelatinase-associated lipocalin (NGAL) in a mouse model of cisplatin-induced nephrotoxic injury. Methods: Mice were subjected to intraperitoneal injections of 20 mg/kg (high dose) or 5 mg/kg (low dose) cisplatin. The expression of NGAL was measured in the kidney and urine by Western analysis and immunofluorescence, and compared to changes in serum creatinine and urinary N-acetyl-β-D-glucosaminidase (NAG). Results: Cisplatin resulted in tubule cell necrosis and apoptosis following the high dose, but not the low dose. By Western analysis, NGAL protein was rapidly induced in the kidney within 3 h of high-dose cisplatin. By immunofluorescence, NGAL was induced predominantly in proximal tubule cells in a punctate cytoplasmic distribution, reminiscent of a secreted protein. NGAL was easily detected in the urine by Western analysis within 3 h of cisplatin administration in a dose- and duration-dependent manner. By comparison, changes in urinary NAG or serum creatinine were not evident until 96 h after cisplatin. Using defined concentrations of purified recombinant NGAL, urinary NGAL excretion following cisplatin administration was quantified to be in the 20–80 ng/ml range. Conclusion: The results indicate that NGAL represents an early and quantitative urinary biomarker for cisplatin nephrotoxicity.

Keywords:
Nephrotoxicity, Cisplatin, Urinary biomarkers, Acute renal failure, Lipocalin
1.
Lebwohl D, Canetta R: Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer 1998;34:1522–1534.
2.
Trimmer EE, Essigmann JM: Cisplatin. Essays Biochem 1999;34:191–211.
3.
Humes HD: Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci 1999;884:15–18.
4.
Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460–464.
5.
Leibbrandt MEI, Wolfgang GHI, Metz AL, Ozobia AA, Haskins JR: Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 1995;48:761–770.
6.
Park MS, De Leon M, Devarajan P: Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002;13:858–865.
7.
Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH: Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1–10.
8.
Hanigan MH, Devarajan P: Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Therapy 2003;1:47–61.
9.
Liu H, Baliga R: Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 2003;63:1687–1696.
10.
Meyer KB, Madias NE: Cisplatin nephrotoxicity. Miner Electrolyte Metab 1994;20:201–213.
11.
Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV: Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother Pharmacol 2003;52:13–18.
12.
Star RA: Treatment of acute renal failure. Kidney Int 1998;54:1817–1831.
13.
Lamiere N, Vanholder R: Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol 2001;12:S20–S32.
14.
Sheikh-Hamad D, Timmins K, Jalali Z: Cisplatin-induced renal toxicity: Possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 1997;8:1640–1645.
15.
Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 1996;334:1448–1460.
16.
Nolan CR, Anderson RJ: Hospital acquired acute renal failure. J Am Soc Nephrol 1998;9:710–718.
17.
Moran SM, Myers BD: Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985;27:928–937.
18.
Muramatsu Y, Tsujie M, Kohda Y, Pham B, Perantoni AO, Zhao H, Jo S-K, Yuen PST, Craig L, Hu X, Star RA: Early detection of cysteine-rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 2002;62:1601–1610.
19.
Rabb H: Novel urinary markers for early diagnosis of ARF. Am J Kidney Dis 2003;42:599–600.
20.
Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV: Kidney injury molecule-1 (KIM-1): A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2003;286:F552–F563.
21.
Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P: Differential gene expression following early renal ischemia-reperfusion. Kidney Int 2003;63:1714–1724.
22.
Xu S, Venge P: Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000;1482:298–307.
23.
Yang J, Goetz D, Li JY, Wand W, Mori K, Setlik D, Du T, Erdjument-Bromage H, Tempst P, Strong R, Barasch J: An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045–1056.
24.
Yang J, Mori K, Li JY, Barasch J: Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 2003;285:F9–F18.
25.
Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of NGAL as a novel urinary biomarker for ischemic injury. J Am Soc Nephrol 2003;14:2534–2543.
26.
Megyesi J, Safirstein RL, Price PM: Induction of p21WAF/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998;101:777–782.
27.
Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick HS, Agarwal A: Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 2000;278:F726–F736.
28.
Ramesh G, Reeves WB: TNF-1 mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835–842.
29.
Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M: Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 2003;63:72–82.
30.
Bundgaard J, Sengelov H, Borregaard N, Kjeldsen L: Molecular cloning and expression of a cDNA encoding Ngal: A lipocalin expressed in human neutrophils. Biochem Biophys Res Commun 1994;202:1468–1475.
31.
Del Rio M, Imam A, De Leon M, Gomez G, Mishra J, Ma Q, Parikh S, Devarajan P: The death domain of kidney ankyrin interacts with Fas and promotes Fas-mediated cell death in renal epithelia. J Am Soc Nephrol 2004;15:41–51.
32.
Kjeldsen L, Cowland JB, Borregaard N: Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000;1482:272–283.
33.
Hraba-Renevey S, Turler H, Kress M, Salomon C, Weil R: SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. Oncogene 1989;4:601–608.
34.
Cowland JB, Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17–23.
35.
Bailly V, Zhang Z, Meier W, Cate R, Sanicola M, Bonventre JV: Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem 2002;277:39739–39748.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.